CA2776751C - Methods to predict clinical outcome of cancer - Google Patents

Methods to predict clinical outcome of cancer Download PDF

Info

Publication number
CA2776751C
CA2776751C CA2776751A CA2776751A CA2776751C CA 2776751 C CA2776751 C CA 2776751C CA 2776751 A CA2776751 A CA 2776751A CA 2776751 A CA2776751 A CA 2776751A CA 2776751 C CA2776751 C CA 2776751C
Authority
CA
Canada
Prior art keywords
il6st
normalized
level
breast cancer
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2776751A
Other languages
English (en)
French (fr)
Other versions
CA2776751A1 (en
Inventor
Joffre B. Baker
Maureen T. Cronin
Francois Collin
Mei-lan LIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomic Health Inc
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Priority to CA3043089A priority Critical patent/CA3043089A1/en
Publication of CA2776751A1 publication Critical patent/CA2776751A1/en
Application granted granted Critical
Publication of CA2776751C publication Critical patent/CA2776751C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2776751A 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer Active CA2776751C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3043089A CA3043089A1 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26376309P 2009-11-23 2009-11-23
US61/263,763 2009-11-23
PCT/US2010/057490 WO2011063274A2 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3043089A Division CA3043089A1 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer

Publications (2)

Publication Number Publication Date
CA2776751A1 CA2776751A1 (en) 2011-05-26
CA2776751C true CA2776751C (en) 2019-07-02

Family

ID=44060376

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2776751A Active CA2776751C (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer
CA3043089A Withdrawn CA3043089A1 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3043089A Withdrawn CA3043089A1 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer

Country Status (13)

Country Link
US (4) US20110123990A1 (cg-RX-API-DMAC7.html)
EP (4) EP4350001A3 (cg-RX-API-DMAC7.html)
JP (7) JP5964752B2 (cg-RX-API-DMAC7.html)
AU (1) AU2010321829B2 (cg-RX-API-DMAC7.html)
CA (2) CA2776751C (cg-RX-API-DMAC7.html)
DK (1) DK2504451T3 (cg-RX-API-DMAC7.html)
ES (1) ES2735993T3 (cg-RX-API-DMAC7.html)
HU (1) HUE044374T2 (cg-RX-API-DMAC7.html)
IL (5) IL219051A (cg-RX-API-DMAC7.html)
MX (3) MX391499B (cg-RX-API-DMAC7.html)
NZ (1) NZ599194A (cg-RX-API-DMAC7.html)
PL (1) PL2504451T3 (cg-RX-API-DMAC7.html)
WO (1) WO2011063274A2 (cg-RX-API-DMAC7.html)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP2163650B1 (en) 2004-04-09 2015-08-05 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
PL1836629T3 (pl) * 2004-11-05 2020-06-15 Genomic Health, Inc. Przewidywanie odpowiedzi na chemioterapię z zastosowaniem markerów ekspresji genu
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
CN102132160A (zh) * 2008-06-26 2011-07-20 达纳-法伯癌症研究院有限公司 与转移有关的信号和决定子以及它们的使用方法及用途
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
AU2010321829B2 (en) * 2009-11-23 2015-07-30 Genomic Health, Inc. Methods to predict clinical outcome of cancer
NZ705645A (en) 2010-01-11 2016-05-27 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
EP3812469A1 (en) 2010-07-07 2021-04-28 Myriad Genetics, Inc. Gene signatures for cancer prognosis
SG186940A1 (en) 2010-07-27 2013-02-28 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
US9605319B2 (en) 2010-08-30 2017-03-28 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
US20140113297A1 (en) * 2011-03-26 2014-04-24 Oregon Health & Science University Gene expression predictors of cancer prognosis
WO2012178087A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
WO2013006495A2 (en) * 2011-07-01 2013-01-10 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
KR102003660B1 (ko) * 2011-07-13 2019-07-24 더 멀티플 마이얼로머 리서치 파운데이션, 인크. 데이터 수집 및 분배 방법
WO2013025952A2 (en) * 2011-08-16 2013-02-21 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of breast cancer
EP2776830B1 (en) * 2011-11-08 2018-05-09 Genomic Health, Inc. Method of predicting breast cancer prognosis
JP5805518B2 (ja) * 2011-12-21 2015-11-04 株式会社島津製作所 マルチプレックス大腸がんマーカーパネル
HK1201881A1 (en) 2012-01-31 2015-09-11 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
WO2013159099A2 (en) * 2012-04-20 2013-10-24 Memorial Sloan-Kettering Cancer Center Gene expression profiles associated with metastatic breast cancer
US20150299799A1 (en) 2012-10-05 2015-10-22 Michael Sturzl Method for Detecting an Increased Risk or Incidence of Colorectal Cancer
CA2891653A1 (en) 2012-11-16 2014-05-22 Myriad Genetics, Inc. Gene signatures for cancer prognosis
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
WO2014194078A1 (en) * 2013-05-30 2014-12-04 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
US10392667B2 (en) * 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
US20170073763A1 (en) * 2014-03-12 2017-03-16 The Board Of Trustees Of The Leland Stanford Junior University Methods and Compositions for Assessing Patients with Non-small Cell Lung Cancer
EP3143160B1 (en) 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
DK3198035T3 (da) 2014-09-26 2023-01-30 Allarity Therapeutics Europe ApS Fremgangsmåder til forudsigelse af medicinrespons
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
CN107532124B (zh) 2015-03-27 2022-08-09 精密科学公司 检测食管疾病
AU2016343937B2 (en) 2015-10-30 2023-01-19 Exact Sciences Corporation Multiplex amplification detection assay and isolation and detection of DNA from plasma
CA3008273A1 (en) 2015-12-18 2017-06-22 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
US11680298B2 (en) 2016-09-07 2023-06-20 Agency For Science, Technology And Research Method of identifying risk of cancer and therapeutic options
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
EP3574110A4 (en) 2017-01-27 2021-01-13 Exact Sciences Development Company, LLC DETECTION OF COLUMN NEOPLASIA BY ANALYSIS OF METHYLATED DNA
WO2018212192A1 (ja) * 2017-05-18 2018-11-22 京都府公立大学法人 癌の予後及び/又は転移可能性を評価する方法及びマーカー
US12275994B2 (en) * 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
KR102424222B1 (ko) 2017-11-13 2022-07-21 더 멀티플 마이얼로머 리서치 파운데이션, 인크. 통합된, 분자, 체학, 면역요법, 대사, 후성적, 및 임상 데이터베이스
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
US11198911B2 (en) * 2018-03-08 2021-12-14 University Of Notre Dame Du Lac Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
JP7444376B2 (ja) * 2018-09-21 2024-03-06 国立大学法人 東京大学 がんの予後判定方法
JP2019032334A (ja) * 2018-10-03 2019-02-28 イムノヴィア・アクチエボラーグ 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
JP2022512152A (ja) * 2018-12-08 2022-02-02 ピーエフエス・ジェノミクス・インコーポレイテッド 乳がんの予後についてのトランスクリプトームプロファイリング
JP7584151B2 (ja) * 2019-05-03 2024-11-15 ディーシージェン カンパニー リミテッド 癌の予後予測方法およびその組成物
CN111235270B (zh) * 2019-08-29 2022-04-29 北京臻知医学科技有限责任公司 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒
US12165747B2 (en) * 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
WO2022174089A1 (en) * 2021-02-12 2022-08-18 Mammogen, Inc. Biomarkers for the diagnosis of breast cancer
WO2022192128A2 (en) * 2021-03-08 2022-09-15 Castle Biosciences, Inc. Determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores
CN117116345B (zh) * 2023-07-24 2025-09-16 中国人民解放军军事科学院军事医学研究院 一种基于基因调控网络构建患者生存网络的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US7514209B2 (en) * 2001-06-18 2009-04-07 Rosetta Inpharmatics Llc Diagnosis and prognosis of breast cancer patients
US7705120B2 (en) * 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ATE529535T1 (de) * 2002-03-13 2011-11-15 Genomic Health Inc Genexpressionsprofilierung in einer biopsie unterzogenem tumorgewebe
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP3330875B1 (en) * 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
JP2007527247A (ja) * 2004-03-05 2007-09-27 ロゼッタ インファーマティクス エルエルシー 臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類
US20080299550A1 (en) * 2004-09-20 2008-12-04 Bayer Healthcare Ag Methods and Kits For the Prediction of Therapeutic Success and Recurrence Free Survival In Cancer Therapy
WO2006103442A2 (en) * 2005-04-01 2006-10-05 Ncc Technology Ventures Pte. Ltd. Materials and methods relating to breast cancer classification
WO2006133460A2 (en) * 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
US7888019B2 (en) * 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
EP2140025A2 (en) * 2007-04-16 2010-01-06 Ipsogen Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
WO2009095319A1 (en) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
ES2403220T3 (es) * 2008-05-12 2013-05-16 Genomic Health, Inc. Pruebas para predecir la receptividad de pacientes con cáncer a opciones de tratamiento con quimioterapia
AU2010321829B2 (en) * 2009-11-23 2015-07-30 Genomic Health, Inc. Methods to predict clinical outcome of cancer

Also Published As

Publication number Publication date
WO2011063274A2 (en) 2011-05-26
US20170211154A1 (en) 2017-07-27
JP2021058207A (ja) 2021-04-15
JP7042717B2 (ja) 2022-03-28
EP3556867A1 (en) 2019-10-23
EP4350001A2 (en) 2024-04-10
JP2013514058A (ja) 2013-04-25
AU2010321829B2 (en) 2015-07-30
CA3043089A1 (en) 2011-05-26
US20210062275A1 (en) 2021-03-04
JP5964752B2 (ja) 2016-08-03
NZ599194A (en) 2014-07-25
MX337650B (es) 2016-03-14
JP2018196385A (ja) 2018-12-13
JP2022166064A (ja) 2022-11-01
JP2024037948A (ja) 2024-03-19
IL264072A (en) 2019-02-28
IL219051A0 (en) 2012-06-28
IL276487A (en) 2020-09-30
MX363817B (es) 2019-04-04
DK2504451T3 (da) 2019-08-05
EP2504451B1 (en) 2019-06-05
HUE044374T2 (hu) 2019-10-28
IL257063B (en) 2019-01-31
ES2735993T3 (es) 2019-12-23
MX2019003811A (es) 2019-08-05
PL2504451T3 (pl) 2019-09-30
EP3739060A1 (en) 2020-11-18
US20110123990A1 (en) 2011-05-26
EP4350001A3 (en) 2024-06-19
IL249159A0 (en) 2017-01-31
MX2012005822A (es) 2012-06-19
AU2010321829A1 (en) 2012-05-03
WO2011063274A3 (en) 2014-03-27
JP2016214245A (ja) 2016-12-22
JP2022169647A (ja) 2022-11-09
IL219051A (en) 2016-12-29
IL276487B (en) 2022-03-01
EP2504451A2 (en) 2012-10-03
US20190241967A1 (en) 2019-08-08
MX391499B (es) 2025-03-21
CA2776751A1 (en) 2011-05-26
IL264072B (en) 2020-08-31
EP2504451A4 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
CA2776751C (en) Methods to predict clinical outcome of cancer
CA2804626C (en) Method for using expression of glutathione s-transferase mu 2 (gstm2) to determine prognosis of prostate cancer
JP4680898B2 (ja) 癌再発の可能性の予測
JP4723472B2 (ja) 乳癌予後診断のための遺伝子発現マーカー
JP6351112B2 (ja) 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
JP2006506093A (ja) Egfr陽性癌の遺伝子発現プロファイリング
JP2006506093A5 (cg-RX-API-DMAC7.html)
WO2009026128A2 (en) Gene expression markers of recurrence risk in cancer patients after chemotherapy
US20120004127A1 (en) Gene expression markers for colorectal cancer prognosis
JP7239477B2 (ja) 前立腺がんにおける後期臨床エンドポイントを評価するためのアルゴリズムおよび方法
US20110287958A1 (en) Method for Using Gene Expression to Determine Colorectal Tumor Stage
HK40107615A (en) Methods to predict clinical outcome of cancer
HK40043378A (en) Methods to predict clinical outcome of cancer
HK40014990A (en) Methods to predict clinical outcome of cancer
HK1175820B (en) Methods to predict clinical outcome of cancer
HK1175820A (en) Methods to predict clinical outcome of cancer
NZ711680A (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151116